Biological agents and ionizing radiation lead to more severe clinical outcomes than either insult alone. This study investigated the survival of non-irradiated and 60Co-gamma-irradiated mice given therapy for inhalation anthrax with ciprofloxacin (CIP) or a clinically relevant mixture of clarithromycin (CLR) and its major human microbiologically important metabolite 14-hydroxy clarithromycin (14-OH CLR). All B6D2F1/J 10-week-old female mice were inoculated intratracheally with 3 × 108 c.f.u. of Bacillus anthracis Sterne spores 4 days after the non-lethal 7 Gy dose of 60Co gamma radiation. Twenty-one days of treatment with CLR/14-OH CLR, 150 mg kg−1 twice daily, or CIP, 16.5 mg kg−1 twice daily, began 24 h after inoculation. Pharmacokinetics indicate that the area under the curve (AUC) for 14-OH CLR on the concentration-versus-time graph was slightly higher in gamma-irradiated than non-irradiated animals. Neither drug was able to increase survival in gamma-irradiated animals. CIP and CLR/14-OH CLR therapies in non-irradiated animals increased survival from 49 % (17/35 mice) in buffer-treated animals to 94 % (33/35) and 100 %, respectively (P < 0.001). B. anthracis Sterne only was isolated from 25–50 % of treated mice with or without irradiation. Mixed infections with B. anthracis Sterne were present in 50–71 % of gamma-irradiated mice but only in 5–10 % of mice without irradiation.
AnzuetoA.,
NorrisS.2004; Clarithromycin in 2003: sustained efficacy and safety in an era of rising antibiotic resistance. Int J Antimicrob Agents 24:1–17
AthamnaA.,
MassalhaM.,
AthamnaM.,
NuraA.,
MedlejB.,
OfekI.,
BastD.,
RubinsteinE.2004; In vitro susceptibility of Bacillus anthracis to various antibacterial agents and their time-kill activity. J Antimicrob Chemother 53:247–251[CrossRef]
BrookI.,
ElliottT. B.,
HardingR. A.,
BouhaoualaS. S.,
PeacockS. J.,
LedneyG. D.,
KnudsonG. B.2001a; Susceptibility of irradiated mice to Bacillus anthracis Sterne by the intratracheal route of infection. J Med Microbiol 50:702–711
BrookI.,
ElliottT. B.,
PryorH. I.,
SautterT. E.,
GnadeB. T.,
ThakarJ. H.,
KnudsonG. B.2001b; In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones. Int J Antimicrob Agents 18:559–562[CrossRef]
Centers for Disease Control and Prevention; 2001; Update: investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb Mortal Wkly Rep 50:909–919
DewanP. K.,
FryA. M.,
LasersonK. & 16 other authors; 2002; Inhalational anthrax outbreak among postal workers. Washington, D.C: 2001Emerg Infect Dis 8:1066–1072[CrossRef]
ElliottT. B.,
LedneyG. D.,
HardingR. A.,
HendersonP. L.,
GerstenbergH. M.,
RotruckJ. R.,
VerdolinM. H.,
StilleC. M.,
KriegerA. G.1995; Mixed-field neutrons and γ-photons induce different changes in ileal bacteria and correlated sepsis in mice. Int J Radiat Biol 68:311–320[CrossRef]
FranzD. R.,
JahrlingP. B.,
FriedlanderA. M.,
McClainD. J.,
HooverD. L.,
BryneW. R.,
PavlinJ. A.,
ChristopherG. W.,
EitzenE. M.Jr1997; Clinical recognition and management of patients exposed to biological warfare agents. JAMA 278:399–411[CrossRef]
FreanJ.,
KlugmanK. P.,
ArntzenL.,
BukofzerS.2003; Susceptibility of Bacillus anthracis to eleven antimicrobial agents including novel fluoroquinolones and a ketolide. J Antimicrob Chemother 52:297–299[CrossRef]
InglesbyT. V.,
HendersonD. A.,
BartlettJ. G. & 11 other authors; 1999; Anthrax as a biological weapon: medical and public health management.Working Group on Civilian Biodefense. JAMA 281:1735–1745[CrossRef]
National Research Council.1996Guide for the Care and Use of Laboratory Animals Washington, D.C.: Institute of Laboratory Animal Resources Commission on Life Sciences;
OnyejiC. O.,
BuiK. Q.,
OwensR. C.Jr,
NicolauD. P.,
QuintilianiR.,
NightingaleC. H.1999; Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia. Int J Antimicrob Agents 12:107–114[CrossRef]
TessierP. R.,
KimM. K.,
ZhouW.,
XuanD.,
LiC.,
YeM.,
NightingaleC. H.,
NicolauD. P.2002; Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia. Antimicrob Agents Chemother 46:1425–1434[CrossRef]
World Health Organization1970Health Aspects of Chemical and Biological Weapons: a Report of a WHO Group of Consultants Geneva, Switzerland: World Health Organization;